Chemomab Therapeutics Ltd. CMMB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-66.4
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$9.0M | — | -$11.1M | $12.3M |
| 2024 | — | -$13.9M | — | -$15.4M | $13.5M |
| 2023 | — | -$24.2M | — | -$23.6M | $17.0M |
| 2022 | — | -$27.6M | — | -$20.4M | $36.2M |
| 2021 | — | -$12.5M | — | -$12.6M | $61.5M |
| 2020 | — | -$6.0M | — | -$5.3M | $10.8M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -66.4 (distress)
- Working capital / assets 0.865
- Retained earnings / assets -8.081
- EBIT / assets -8.109
- Equity / liabilities 8.345
Source: SEC EDGAR filings · CIK 0001534248 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.